WASHINGTON, D.C. - Fifteen amicus curiae briefs from drug companies, drug trade associations, congressmen, former Food and Drug Administration commissioners, law professors, advocacy groups and even a case expert have been filed in the U.S. Supreme Court appeal that will determine if design defect claims involving generic prescription drugs are preempted by federal law (Mutual Pharmaceutical Company, Inc. v. Karen L. Bartlett, No. 12-142, U.S. Sup.; See 7/12/12, Page 20)....(read more)![]()
↧
